Welcure Drugs and Pharmaceuticals Limited (BOM:524661)
India
· Delayed Price · Currency is INR 0.280
-0.010 (-3.45%)
At close: Mar 10, 2026
BOM:524661 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 3,655 | 245.5 | - | - | 1.05 | 1.33 | Upgrade
|
| Revenue Growth (YoY) | 994.82% | - | - | - | -21.26% | 61.63% | Upgrade
|
| Cost of Revenue | 3,205 | 205.05 | - | - | - | - | Upgrade
|
| Gross Profit | 450.48 | 40.45 | - | - | 1.05 | 1.33 | Upgrade
|
| Selling, General & Admin | 2.62 | 4.47 | 1.03 | 0.42 | 0.13 | 0.77 | Upgrade
|
| Other Operating Expenses | 0.4 | 8.11 | -2.25 | -0.87 | 0.68 | 0.01 | Upgrade
|
| Operating Expenses | 3.16 | 12.65 | -0.86 | -0.41 | 0.81 | 0.78 | Upgrade
|
| Operating Income | 447.32 | 27.8 | 0.86 | 0.41 | 0.24 | 0.55 | Upgrade
|
| Interest & Investment Income | - | - | 0.58 | 0.44 | - | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | 14.64 | - | 0.01 | - | - | -0 | Upgrade
|
| EBT Excluding Unusual Items | 461.96 | 27.8 | 1.45 | 0.86 | 0.24 | 0.55 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -3.2 | 0.16 | - | - | Upgrade
|
| Pretax Income | 461.96 | 27.8 | -1.75 | 1.02 | 0.24 | 0.55 | Upgrade
|
| Income Tax Expense | 15.79 | 6.1 | - | - | - | - | Upgrade
|
| Net Income | 446.17 | 21.7 | -1.75 | 1.02 | 0.24 | 0.55 | Upgrade
|
| Net Income to Common | 446.17 | 21.7 | -1.75 | 1.02 | 0.24 | 0.55 | Upgrade
|
| Net Income Growth | 2262.32% | - | - | 331.31% | -57.24% | - | Upgrade
|
| Shares Outstanding (Basic) | 1,718 | 859 | 149 | 148 | 133 | 133 | Upgrade
|
| Shares Outstanding (Diluted) | 1,718 | 859 | 149 | 148 | 133 | 133 | Upgrade
|
| Shares Change (YoY) | 78.83% | 477.75% | 0.54% | 10.90% | - | - | Upgrade
|
| EPS (Basic) | 0.26 | 0.03 | -0.01 | 0.01 | 0.00 | 0.00 | Upgrade
|
| EPS (Diluted) | 0.26 | 0.03 | -0.01 | 0.01 | 0.00 | 0.00 | Upgrade
|
| EPS Growth | 1221.06% | - | - | 284.56% | -57.25% | - | Upgrade
|
| Free Cash Flow | - | -2,220 | -1.28 | 1.07 | 0.19 | 0.42 | Upgrade
|
| Free Cash Flow Per Share | - | -2.59 | -0.01 | 0.01 | 0.00 | 0.00 | Upgrade
|
| Gross Margin | 12.32% | 16.48% | - | - | 100.00% | 100.00% | Upgrade
|
| Operating Margin | 12.24% | 11.32% | - | - | 22.46% | 41.26% | Upgrade
|
| Profit Margin | 12.21% | 8.84% | - | - | 22.46% | 41.36% | Upgrade
|
| Free Cash Flow Margin | - | -904.46% | - | - | 17.67% | 31.64% | Upgrade
|
| EBITDA | 447.18 | 27.88 | 1.22 | 0.44 | - | - | Upgrade
|
| EBITDA Margin | 12.23% | 11.36% | - | - | - | - | Upgrade
|
| D&A For EBITDA | -0.14 | 0.08 | 0.36 | 0.03 | - | - | Upgrade
|
| EBIT | 447.32 | 27.8 | 0.86 | 0.41 | 0.24 | 0.55 | Upgrade
|
| EBIT Margin | 12.24% | 11.32% | - | - | 22.46% | 41.26% | Upgrade
|
| Effective Tax Rate | 3.42% | 21.94% | - | - | - | - | Upgrade
|
| Revenue as Reported | 3,689 | 264.6 | 0.94 | 2.37 | 1.05 | 1.34 | Upgrade
|
| Advertising Expenses | - | 0.07 | - | 0.02 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.